For: | Fang YT, Yang WW, Niu YR, Sun YK. Recent advances in targeted therapy for pancreatic adenocarcinoma. World J Gastrointest Oncol 2023; 15(4): 571-595 [PMID: 37123059 DOI: 10.4251/wjgo.v15.i4.571] |
---|---|
URL: | https://www.wjgnet.com/1948-5204/full/v15/i4/571.htm |
Number | Citing Articles |
1 |
Riley J. Arseneau, Emma Kempster, Carley Bekkers, Thomas Samson, Boris L. Gala-Lopez, Ravi Ramjeesingh, Jeanette E. Boudreau, Thomas Arnason. Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy. Translational Oncology 2025; 55: 102362 doi: 10.1016/j.tranon.2025.102362
|
2 |
Fabio Scianò, Francesca Terrana, Camilla Pecoraro, Barbara Parrino, Stella Cascioferro, Patrizia Diana, Elisa Giovannetti, Daniela Carbone. Exploring the Therapeutic Potential of Focal Adhesion Kinase Inhibition in Overcoming Chemoresistance in Pancreatic Ductal Adenocarcinoma. Future Medicinal Chemistry 2024; 16(3): 271 doi: 10.4155/fmc-2023-0234
|
3 |
Chunxiao Ren, Yuqun Wang, Xin Yang, Yinglan Tuo, Yaqiong Li, Jichang Gong. Kikuchi disease: A case report about Sintilimab-induced Kikuchi histiocytic necrotizing lymphadenitis and literature review. Heliyon 2024; 10(9): e30608 doi: 10.1016/j.heliyon.2024.e30608
|
4 |
Diego J. Jiménez, Aadil Javed, Teresa Rubio-Tomás, Ndioba Seye-Loum, Carles Barceló. Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer. International Journal of Molecular Sciences 2024; 25(5): 2860 doi: 10.3390/ijms25052860
|
5 |
Karl Knipper, Yussra Hussein, Adrian Georg Simon, Caroline Fretter, Alexander I. Damanakis, Yue Zhao, Christiane J. Bruns, Thomas Schmidt, Felix C. Popp, Alexander Quaas, Su Ir Lyu, Michael Heise, Frank Marusch, Marco Siech, Tawfik Mosa, Bodo Schniewind, Jürgen Tepel, Werner Hartwig, Christoph Prinz, Bettina M. Rau, Marco Niedergethmann, Rainer Kube, George Saada, Wolfgang Hiller, Utz Settmacher. Upregulation of the histone γ-H2AX correlates with worse patient survival and basal-like subtype in pancreatic ductal adenocarcinoma. Journal of Cancer Research and Clinical Oncology 2024; 150(3) doi: 10.1007/s00432-024-05681-x
|
6 |
Hiroo Imai, Yasuhiro Sakamoto, Shin Takahashi, Hiroyuki Shibata, Atsushi Sato, Kazunori Otsuka, Kenji Amagai, Masanobu Takahashi, Takuhiro Yamaguchi, Chikashi Ishioka. Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201). BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-11973-9
|
7 |
Rawaa AlChalabi, Raghda Makia, Semaa A. Shaban, Ahmed AbdulJabbar Suleiman. Characterizing immune biomarkers and effector CD8+ T-cell exhaustion in pancreatic adenocarcinoma via single-cell RNA sequencing profiling. Exploration of Immunology 2025; doi: 10.37349/ei.2025.1003179
|
8 |
Jinglong Guo, Siyue Wang, Qi Gao. An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1258538
|
9 |
Somayeh Jafari, Hossein Motedayyen, Parisa Javadi, Kazem Jamali, Amin Moradi Hasan-Abad, Amir Atapour, Gholamreza Anani Sarab. The roles of lncRNAs and miRNAs in pancreatic cancer: a focus on cancer development and progression and their roles as potential biomarkers. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1355064
|
10 |
Stefanie Höfer, Larissa Frasch, Sarah Brajkovic, Kerstin Putzker, Joe Lewis, Hendrik Schürmann, Valentina Leone, Amirhossein Sakhteman, Matthew The, Florian P Bayer, Julian Müller, Firas Hamood, Jens T Siveke, Maximilian Reichert, Bernhard Kuster. Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response. Molecular Systems Biology 2025; 21(3): 231 doi: 10.1038/s44320-025-00085-6
|
11 |
Chao Liu, Jiang Du, Jianwei Zheng, Ruizhe Zhang, Jialin Zhu, Bofan Xing, Lin Dong, Qianqian Zhou, Xiaofeng Yao, Song Gao, Yu Wang, Yu Ren, Xuan Zhou. The role of BHLHE40 in clinical features and prognosis value of PDAC by comprehensive analysis and in vitro validation. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1151321
|
12 |
Su Ir Lyu, Caroline Fretter, Adrian Georg Simon, Sarah-Michele Spielmann, Alexander I. Damanakis, Yue Zhao, Christiane J. Bruns, Thomas Schmidt, Felix C. Popp, Dirk Waldschmidt, Alexander Quaas, Karl Knipper. Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence. Translational Oncology 2024; 47: 102044 doi: 10.1016/j.tranon.2024.102044
|
13 |
Sashikanta Swain, Ravi Kant Narayan, Pravash Ranjan Mishra. Unraveling the interplay: exploring signaling pathways in pancreatic cancer in the context of pancreatic embryogenesis. Frontiers in Cell and Developmental Biology 2024; 12 doi: 10.3389/fcell.2024.1461278
|
14 |
Kritisha Bhandari, Wei-Qun Ding. Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy. International Journal of Molecular Sciences 2024; 25(7): 3958 doi: 10.3390/ijms25073958
|
15 |
Tenzin Passang, Shuhua Wang, Hanwen Zhang, Fanyuan Zeng, Po-Chih Hsu, Wenxi Wang, Jian-Ming Li, Yuan Liu, Sruthi Ravindranathan, Gregory B. Lesinski, Edmund K. Waller. VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer. Cancer Research 2024; 84(18): 2954 doi: 10.1158/0008-5472.CAN-23-3628
|
16 |
Craig Grobbelaar, Vanessa Steenkamp, Peace Mabeta. Vascular Endothelial Growth Factor Receptors in the Vascularization of Pancreatic Tumors: Implications for Prognosis and Therapy. Current Issues in Molecular Biology 2025; 47(3): 179 doi: 10.3390/cimb47030179
|
17 |
Clare Chen, Lusine Demirkhanyan, Christopher S. Gondi. The Multifaceted Role of miR-21 in Pancreatic Cancers. Cells 2024; 13(11): 948 doi: 10.3390/cells13110948
|
18 |
Deepak Bhamidipati, Sireesha Yedururi, Jason Huse, Sri Veda Chinapuvvula, Jie Wu, Vivek Subbiah. Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer. JCO Precision Oncology 2023; (7) doi: 10.1200/PO.23.00252
|
19 |
Boyu Qin, Qi Xiong, Lingli Xin, Ke Li, Weiwei Shi, Qi Song, Qiong Sun, Jiakang Shao, Jing Zhang, Xiao Zhao, Jinyu Liu, Jinliang Wang, Bo Yang. Synergistic effect of additional anlotinib and immunotherapy as second‐line or later‐line treatment in pancreatic cancer: A retrospective cohort study. Cancer Innovation 2024; 3(4) doi: 10.1002/cai2.123
|
20 |
Akash Bararia, Amlan Das, Sangeeta Mitra, Sudeep Banerjee, Aniruddha Chatterjee, Nilabja Sikdar. Deoxyribonucleic acid methylation driven aberrations in pancreatic cancer-related pathways. World Journal of Gastrointestinal Oncology 2023; 15(9): 1505-1519 doi: 10.4251/wjgo.v15.i9.1505
Abstract(677) |
Core Tip(664) |
Full Article(HTML)(3518)
|
Full Article with Cover (PDF)-2302K(133)
|
Full Article (Word)-641K(58)
|
Audio-449K(3)
|
Peer-Review Report-207K(85)
|
Answering Reviewers-146K(84)
|
Full Article (PDF)-2009K(170)
|
Full Article (XML)-278K(81)
|
Times Cited (1)
|
Total Visits (7908)
|
Open
|
21 |
Erika Stefàno, Gianluca Rovito, Luca G. Cossa, Federica De Castro, Viviana Vergaro, Asjad Ali, Giulia My, Danilo Migoni, Antonella Muscella, Santo Marsigliante, Michele Benedetti, Francesco Paolo Fanizzi, Massimiliano F. Peana. Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells. Bioinorganic Chemistry and Applications 2024; 2024(1) doi: 10.1155/bca/5588491
|